Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Threshold out-licenses TH302 to Merck Serono; Phase III trials fail and deal ends

Executive Summary

Threshold Pharmaceuticals Inc. (cancer drug development) has granted Merck KGAA’s Merck Serono SA division rights to co-develop and exclusively sell globally its TH302, a hypoxia-targeted compound in Phase III trials for soft tissue sarcoma, and in additional studies for other cancers. Threshold retains an option to co-promote in the US, giving it the chance to receive 50% of the profits in that territory.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Co-Promotion
    • Includes Royalty or Profit Split Information

Related Companies

UsernamePublicRestriction

Register